Diabetes Medicine Manufacturer Lupin Pharmaceuticals Will Pay Glumetza Buyers $150 Million Over Alleged Scheme To Delay Generic Version

Top Class Actions’s website and social media posts use affiliate links. If you make a purchase using such links, we may receive a commission, but it will not result in any additional charges to you. Please review our Affiliate Link Disclosure for more information.

Lupin Pharmaceuticals Class Action Lawsuit Overview:

• Who: Lupin Pharmaceuticals agreed to a $150 million class action settlement with buyers of the blood sugar medication Glumetza.
• Why: Consumers allege Lupin was part of a scheme to delay the launch of a generic version of Glumetza.
• Where: The class action lawsuit was heard in California federal court.

Lupin Pharmaceuticals has agreed to a $150 million class action settlement with consumers over allegations the company was part of a scheme to delay the launch of a generic version of the diabetes blood sugar medication Glumetza. 

The proposed class action settlement — which Lupin will pay in cash — will resolve allegations the company was paid $3 million by Bausch Health and Depomed (now called Assertio Therapeutics Inc.) to delay the release of its generic version of Glumetza. 

A Class of Glumetza buyers alleged the makers of the drug paid Lupin to delay the launch of its generic version of Glumetza, while Bausch and Depomed promised not to launch their own generic versions until a year after Lupin. 

A generic version of Glumetza could have been available to consumers in December 2012, the class action lawsuit alleged, more than three years before Lupin released its generic version in February 2016. 

The delayed release cost consumers hundreds of millions of dollars in overcharges, buyers said in the class action. 

Plaintiffs claim they reviewed a half-million documents and conducted dozens of depositions, along with briefing for Class certification, during the discovery process, according to the settlement motion.  

The agreement comes less than a month before trial was set to begin, Law360 reports. 

This isn’t the first time Lupin has been accused of price fixing medications. The pharmaceutical company agreed to a $1 million class action settlement with consumers last year over claims it worked with other pharmaceutical companies to fix the price of birth control medication. 

Are you a Glumetza user unaware a generic version of the medication could have been released years before it was? Let us know in the comments! 

The plaintiffs are represented by Hagens Berman Sobol Shapiro LLP, Hilliard & Shadowen LLP and Sperling & Slater PC. 

The Glumetza Class Action Lawsuit is In re: Glumetza Antitrust Litigation, Case No. 3:19-cv-05822, in the U.S. District Court for the Northern District of California

Read About More Class Action Lawsuits & Class Action Settlements:

• Why Is There a Recall on Zantac?
• New Class Action Lawsuit Claims Annovis Bio Gave Investors False Optimism During Alzheimer’s Drug Trial
• Judge Protects Purdue Pharma, Sackler Family From Opioid Class Action Lawsuits
• Johnson & Johnson Targeted Overweight Women, Witness in Talcum Powder Cancer Trial Alleges